Justin M. Oldham, Cathryn T. Lee, Zhe Wu, Willis S. Bowman, Janelle Vu Pugashetti, Nam Dao, James Tonkin, Hasan Seede, Gabrielle Echt, Ayodeji Adegunsoye, Felix Chua, Toby M. Maher, Christine K. Garcia, Mary E. Strek, Chad A. Newton, Philip L. Molyneaux
-
Author contributions: Study design: J.M. Oldham, C.T. Lee, C.A. Newton and P.L. Molyneaux. Data collection: J.M. Oldham, C.T. Lee, Z. Wu, W.S. Bowman, J.V. Pugashetti, N. Dao, J. Tonkin, H. Seede, G. Echt, A. Adegunsoye, C.K. Garcia, C.A. Newton and P.L. Molyneaux. Data analysis: J.M. Oldham and P.L. Molyneaux. Interpretation of results: J.M. Oldham, C.T. Lee, W.S. Bowman, J.V. Pugashetti, A. Adegunsoye, F. Chua, T.M. Maher, C.K. Garcia, M.E. Strek, C.A. Newton and P.L. Molyneaux. Manuscript preparation: J.M. Oldham, C.T. Lee, J.V. Pugashetti, T.M. Maher, M.E. Strek, C.A. Newton and P.L. Molyneaux.
-
This article has supplementary material available from erj.ersjournals.com
-
Conflict of interest: J.M. Oldham reports grants from the National Institutes of Health, during the conduct of the study; personal fees from Boehringer Ingelheim, Genentech, Lupin, Gatehouse Bio and AmMax Bio, outside the submitted work.
-
Conflict of interest: C.T. Lee has nothing to disclose.
-
Conflict of interest: Z. Wu has nothing to disclose.
-
Conflict of interest: W.S. Bowman has nothing to disclose.
-
Conflict of interest: J.V. Pugashetti has nothing to disclose.
-
Conflict of interest: N. Dao has nothing to disclose.
-
Conflict of interest: J. Tonkin has nothing to disclose.
-
Conflict of interest: H. Seede has nothing to disclose.
-
Conflict of interest: G. Echt has nothing to disclose.
-
Conflict of interest: A. Adegunsoye reports grants from the National Institutes of Health, personal fees for lectures and consultancy from Boehringer Ingelheim, personal fees for consultancy from Genentech, outside the submitted work.
-
Conflict of interest: F. Chua has nothing to disclose.
-
Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from AstraZeneca and GlaxoSmithKline R&D, and has received consultancy or lecture fees from AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline R&D, IQVIA, Pliant, Respivant, Roche and Theravance.
-
Conflict of interest: C.K. Garcia has received institutional funding for research from the National Institutes of Health, Dept of Defense and Boehringer Ingelheim, as well as prior compensation from Pliant Therapeutics Inc. for advisory board service.
-
Conflict of interest: M.E. Strek reports grants, personal fees and non-financial support from Boehringer Ingelheim, grants from Novartis, outside the submitted work.
-
Conflict of interest: C.A. Newton reports grants from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (K23HL148498) and NIH National Centre for Advancing Translational Sciences (UL1TR001105), during the conduct of the study; personal fees for consultancy from Boehringer Ingelheim, outside the submitted work.
-
Conflict of interest: P.L. Molyneaux, via his institution, received industry-academic funding from AstraZeneca, and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche, outside the submitted work.
-
Support statement: This work was supported by the National Heart, Lung, and Blood Institute (K23HL138190 (J.M. Oldham); T32HL007605 (C.T. Lee); K23HL146942 (A. Adegunsoye); R01HL093096 (C.K. Garcia); T32HL007013 (W.S. Bowman and J.V. Pugashetti); K23HL148498 (C.A. Newton)) and National Center for Advancing Translational Sciences (UL1TR001105 (C.A. Newton)). P.L. Molyneaux is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship. Funding information for this article has been deposited with the Crossref Funder Registry.